VivoSeq
Oncology

Advanced or Metastatic Solid Tumour

0

Pipeline Programs↗

6

Active Trials↗

8

Companies Involved↗

Advanced or Metastatic Solid Tumour is an early-stage landscape with 0 programs across 8 companies. The most active players are AstraZeneca, Shijiazhuang Yiling Pharmaceutical Co. Ltd, ASLAN Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalS

Shijiazhuang Yiling Pharmaceutical Co. Ltd

0 programs

PreclinicalA

ASLAN Pharmaceuticals

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalA

Aptose Biosciences Inc.

0 programs

PreclinicalA

AGC Biologics S.p.A.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Completed6 · 43%
Recruiting4 · 29%
Active, not recruiting2 · 14%
Unknown status1 · 7%
Terminated1 · 7%

Clinical Trials

Trial Activity

14 trials

A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours
Recruiting·SShijiazhuang Yiling Pharmaceutical Co. Ltd·Phase 1·NCT06027346·60 enrolled
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
Recruiting·IImmVirx Pty Ltd·Phase 1·NCT05427487·70 enrolled
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Recruiting·AstraZeneca logoAstraZeneca·Phase 1/2·NCT06795022·304 enrolled
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
Recruiting·CCullgen (Shanghai),Inc·Phase 1/2·NCT07394374·42 enrolled
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
Active, not recruiting·EElpiscience (Suzhou) Biopharma, Ltd.·Phase 1·NCT05717348·120 enrolled
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT04999969·126 enrolled
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT00969761·61 enrolled
A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours
Completed·AAptose Biosciences Inc.·Phase 1·NCT01281592·36 enrolled
Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour
Completed·AAGC Biologics S.p.A.·Phase 1·NCT00878111·48 enrolled
Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT02610075·62 enrolled
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
Completed·AASLAN Pharmaceuticals·Phase 1·NCT03082053·24 enrolled
A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
Completed·AASLAN Pharmaceuticals·Phase 1·NCT01721148·39 enrolled
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Terminated·CCellestia Biotech AG·Phase 1/2·NCT03422679·79 enrolled
A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours
Unknown status·SShijiazhuang Yiling Pharmaceutical Co. Ltd·Phase 1·NCT03658070·34 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)